Australia's Neuren Pharmaceuticals climbs to two-week high on US FDA designation

Neuren Pharmaceuticals

24/02/2025 01:05

** Shares of Australia's Neuren Pharmaceuticals  NEU.AX 
rise as much as 6.3% to A$14.100, their highest levels since
February 7
    ** Stock on track for its second consecutive session of
gains, if trend holds
    ** The drug manufacturer gets rare paediatric disease
designation from the U.S. Food and Drug Administration (FDA)
    ** Designation for NNZ-2591 in each of Pitt Hopkins syndrome
and Angelman syndrome - Neuren 
    ** NNZ-2591 used for treatment of any traumatic brain injury
   
    ** Stock has risen 11.6% so far this year, as of 0054 GMT

 (Reporting by Roshan Thomas in Bengaluru)
 ((Roshan.Thomas@thomsonreuters.com))